|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085669 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-14 17:02:08 |
|
注册时间: Date of Registration: |
2024-06-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
南京市青少年心理健康风险预警筛查的横断面研究 |
|
Public title: |
A cross-sectional study on adolescent mental health risk early warning and screening in Nanjing |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
南京市青少年心理健康风险预警筛查的横断面研究 |
|
Scientific title: |
A cross-sectional study on adolescent mental health risk early warning and screening in Nanjing |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴腾煜 |
研究负责人: |
孙翔 |
|
Applicant: |
Wu Tengyu |
Study leader: |
Sun Xiang |
|
申请注册联系人电话: Applicant telephone: |
+86 173 6234 6260 |
研究负责人电话:
Study leader's |
+86 153 6517 3126 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wutengyu@rrxmed.com |
研究负责人电子邮件: Study leader's E-mail: |
sunstone1@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
南京市江宁区天元东路2289号瑞鸿科技产业园5号楼B单元三层 |
研究负责人通讯地址: |
南京市江苏路172号 |
|
Applicant address: |
Floor 3, Unit B, Building 5, Ruihong Science and Technology Industrial Park, No.2289, Tianyuan East Road, Jiangning District, Nanjing City |
Study leader's address: |
No.172, Jiangsu Road, Nanjing City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京南药医药科技有限公司 |
||
|
Applicant's institution: |
Nanjing Nanyao Pharmaceutical Technology Co., LTD |
||
|
研究负责人所在单位: |
江苏省疾病预防控制中心 |
||
|
Affiliation of the Leader: |
Jiangsu Provincial Center for Disease Control and Prevention |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
JSJK2024-B004-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
江苏省疾病预防控制中心伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Jiangsu Provincial Center for Disease Prevention and Control |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-29 00:00:00 | ||
|
伦理委员会联系人: |
钱姣 |
||
|
Contact Name of the ethic committee: |
Qian Jiao |
||
|
伦理委员会联系地址: |
南京市江苏路172号A楼222室 |
||
|
Contact Address of the ethic committee: |
Room 222, Building A, No.172, Jiangsu Road, Nanjing city |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 8375 9406 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
ec@jscdc.cn |
|
研究实施负责(组长)单位: |
江苏省疾病预防控制中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Jiangsu Provincial Center for Disease Control and Prevention |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
南京市江苏路172号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.172, Jiangsu Road, Nanjing City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南京南药医药科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Nanjing Nanyao Pharmaceutical Technology Co., LTD |
||||||||||||||||||||||
|
研究疾病: |
抑郁症 |
||||||||||||||||||||||
|
Target disease: |
depression |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
主要目的: 利用十种抑郁症辅助诊断生物标志物(液相色谱-串联质谱法)结合算法对青少年抑郁障碍风险进行筛查预警,结合临床诊断,探讨该方法筛查抑郁障碍的有效性。 次要目的: 1.探讨建立12-15周岁的青少年男性血清中多种代谢物的参考区间; 2.探讨建立16-18周岁的青少年男性血清中多种代谢物的参考区间; 3.探讨建立12-15周岁的青少年女性血清中多种代谢物的参考区间; 4.探讨建立16-18周岁的青少年女性血清中多种代谢物的参考区间; 5.探讨建立南京市青少年抑郁风险辅助筛查工具。 |
||||||||||||||||||||||
|
Objectives of Study: |
fundamental purpose: Ten depression assisted diagnostic biomarkers (liquid chromatography-tandem mass spectrometry) were used to screen the risk of depression disorder, and the effectiveness of this method for depression disorder. Secondary purpose: 1.To explore the establishment of reference intervals for multiple metabolites in the serum of adolescent males aged 12-15 years; 2.To explore the establishment of reference intervals for multiple metabolites in the serum of adolescent males aged 16-18 years; 3.To explore the establishment of reference intervals of multiple metabolites in the serum of adolescent women aged 12-15; 4.To explore the establishment of the reference interval of multiple metabolites in the serum of adolescent women aged 16-18 years old; 5.To explore the establishment of an adolescent depression risk-assisted screening tool in Nanjing. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)样本采集后必须贮存在室温条件下,并在采集后4小时内离心、10小时内转移至-60℃条件下,然后一直存储,直至进行检测; (2)受试者年龄12-18周岁,性别不限; (3)受试者及其法定监护人能够和研究者进行良好的沟通,并且理解和遵守本项研究的各项要求、自愿参与且愿意签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Samples must be stored at room temperature, centrifuged within 4 hours after collection, transferred to-60℃ within 10 hours, and then stored until testing; (2) The subject age is 12-18 years old, and the gender is not limited; (3) The subject and his legal guardian can communicate well with the investigator, understand and comply with the requirements of the study, participate voluntarily, and be willing to sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)样本呈现出凝血或溶血现象; (2)样本的采集或存储不正确; (3)受试者已知患有其他精神类疾病; (4)神经系统病变、脑外伤、心脑血管病患以及严重肝肾功能异常、糖尿病等重大躯体疾病患者; (5)最近一周内正在接受口服或注射激素类药物治疗; (6)近期3个月内有手术史且住院治疗超过1周者; (7研究者认为具有其他不适宜参加本试验因素的样本。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) The sample showed blood coagulation or hemolysis phenomenon; (2) Incorrect collection or storage of samples; (3) The subject is known to have other psychiatric disorders; (4) Patients with neurological diseases, brain trauma, cardiovascular and cerebrovascular diseases, severe liver and kidney function abnormalities, diabetes mellitus and other major physical diseases; (5) Receiving oral treatment or injection of hormone drug therapy in the latest week; (6) Patients with a history of surgery within the recent 3 months and hospitalization for more than 1 week; (7) Samples considered by the investigator to have other inappropriate factors to participate in this trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-06-17 00:00:00至 To 2025-06-17 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-06-17 00:00:00 至 To 2025-06-17 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
有病例记录表 ,无电子采集和管理系统 病历记录表包括:人口学数据,体重指数,既往历史,不符合入选/排除标准记录,筛选结论,样本采集处理,疾病诊断。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
There are case records, and no electronic collection and management system Medical record records include: demographic data, body mass index, past history, records of inclusion / exclusion criteria, screening conclusions, sample collection and processing, and disease diagnosis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |